Literature DB >> 4584346

Human antiserum for prevention of the local shwartzman reaction and death from bacterial lipopolysaccharides.

E J Ziegler, H Douglas, A I Braude.   

Abstract

Bacterial lipopolysaccharides from dead bacteria have been blamed for the continuing high mortality from gram-negative infections despite antibiotic treatment. Because animal antiserum against these lipopolysaccharides has been shown to protect against several of the effects of endotoxin, we undertook the development of antiserum in human subjects. 21 men were immunized with a single injection of Salmonclla typhimurium or Escherichia coli 0:111 heat-killed cells and immune serum was collected at 2 wk. Preimmune serum was obtained as a control in all animal experiments. 1 ml antiserum given intravenously protected mice against a lethal intravenous dose of homologous endotoxin (P < 0.005 for both antisera). E. coli antiserum reduced the incidence of positive local Shwartzman reactions with E. coli endotoxin from 100 to 38%; S. typhimurium antiserum reduced the incidence from 92 to 35%. (P < 0.0005 for both antisera). There was no protection against heterologous endotoxin in either animal model. These experiments demonstrate for the first time that human antiserum confers exceedingly potent passive immunity to the effects of endotoxin.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4584346      PMCID: PMC302600          DOI: 10.1172/JCI107524

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  11 in total

1.  ANTIBODY RESPONSES TO VACCINATION OF BRITISH GUIANA SCHOOLCHILDREN WITH HEART-KILLED-PHENOLIZED AND ACETONE-KILLED LYOPHILIZED TYPHOID VACCINES.

Authors:  M T ASHCROFT; J M RITCHIE; C C NICHOLSON; C A STUART
Journal:  Am J Hyg       Date:  1964-09

2.  Studies with Brucella endotoxin in humans: the significance of susceptibility to endotoxin in the pathogenesis of brucellosis.

Authors:  R S ABERNATHY; W W SPINK
Journal:  J Clin Invest       Date:  1958-02       Impact factor: 14.808

3.  The bacterial hemagglutination test for the demonstration of antibodies to Enterobacteriaceae.

Authors:  E A GORZYNSKI; O LUDERITZ; E NETER; O WESTPHAL
Journal:  Ann N Y Acad Sci       Date:  1956-08-10       Impact factor: 5.691

4.  Treatment of E. coli and klebsiella bacteremia in agranulocytic animals with antiserum to a UDP-gal epimerase-deficient mutant.

Authors:  E J Ziegler; H Douglas; J E Sherman; C E Davis; A I Braude
Journal:  J Immunol       Date:  1973-08       Impact factor: 5.422

5.  Passive immunization against the local Shwartzman reaction.

Authors:  A I Braude; H Douglas
Journal:  J Immunol       Date:  1972-02       Impact factor: 5.422

6.  Characterization of the antibody response to acetone-killed typhoid vaccine.

Authors:  R P May; J A Barnett; J P Sanford
Journal:  Public Health Rep       Date:  1967-03       Impact factor: 2.792

7.  Protection against lethality of E. coli endotoxin with "O" antiserum.

Authors:  W J Tate; H Douglas; A I Braude; W W Wells
Journal:  Ann N Y Acad Sci       Date:  1966-06-30       Impact factor: 5.691

8.  A proposed mechanism for natural immunity to enterobacterial pathogens.

Authors:  L Chedid; M Parant; F Parant; F Boyer
Journal:  J Immunol       Date:  1968-02       Impact factor: 5.422

9.  Prevention of death from endotoxin with antisera. II. Elimination of the risk of anaphylaxis to endotoxin.

Authors:  K R Brown; H Douglas; A I Braude
Journal:  J Immunol       Date:  1971-02       Impact factor: 5.422

10.  Immunization with R mutants of S. Minnesota. I. Protection against challenge with heterologous gram-negative bacilli.

Authors:  W R McCabe
Journal:  J Immunol       Date:  1972-03       Impact factor: 5.422

View more
  13 in total

Review 1.  Bloodstream infections: epidemiology, pathophysiology and therapeutic perspectives.

Authors:  R Salomão; O Rigato; A C Pignatari; M A Freudenberg; C Galanos
Journal:  Infection       Date:  1999 Jan-Feb       Impact factor: 3.553

2.  Mechanisms of endotoxin tolerance. The role of the spleen.

Authors:  S E Greisman; E J Young; J B Workman; R M Ollodart; R B Hornick
Journal:  J Clin Invest       Date:  1975-12       Impact factor: 14.808

3.  Functional role of antibody against "core" glycolipid of Enterobacteriaceae.

Authors:  L S Young; P Stevens; J Ingram
Journal:  J Clin Invest       Date:  1975-10       Impact factor: 14.808

4.  Endotoxin-binding substances from human leukocytes and platelets.

Authors:  G F Springer; J C Adye
Journal:  Infect Immun       Date:  1975-11       Impact factor: 3.441

5.  Polymyxin B sulfate modification of bacterial endotoxin: effects on the development of endotoxin shock in dogs.

Authors:  A H From; J S Fong; R A Good
Journal:  Infect Immun       Date:  1979-03       Impact factor: 3.441

6.  Deficient serum bactericidal activity against Escherichia coli in patients with cirrhosis of the liver.

Authors:  J Fierer; F Finley
Journal:  J Clin Invest       Date:  1979-05       Impact factor: 14.808

7.  Experimental gram-negative bacterial sepsis: prevention of mortality not preventable by antibiotics alone.

Authors:  S E Greisman; J B DuBuy; C L Woodward
Journal:  Infect Immun       Date:  1979-08       Impact factor: 3.441

8.  Prevention of the generalized Shwartzman reaction and endotoxin lethality by polymyxin B localized in tissues.

Authors:  W A Craig; J H Turner; C M Kunin
Journal:  Infect Immun       Date:  1974-08       Impact factor: 3.441

Review 9.  Strategies to improve drug development for sepsis.

Authors:  Mitchell P Fink; H Shaw Warren
Journal:  Nat Rev Drug Discov       Date:  2014-09-05       Impact factor: 84.694

Review 10.  Anti-endotoxin vaccines: back to the future.

Authors:  Alan S Cross
Journal:  Virulence       Date:  2013-08-13       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.